Articles by Dario Trapani

Together with an off-trial use and off-track access to oncology therapies, a consolidated trend is reported in clinical practice despite the uncertainties on efficacy and safety

Recent research shows that tailored strategies and political commitment can revert current epidemiology trends of cancer

Universal health coverage in oncology is still not a reality, as a recent report shows

Increasing data show that they are indicators of inequitable environments which may negatively impact on cancer outcomes, but more efforts are needed to properly assess them in oncology

Adding precision to dose-finding in early-phase clinical trials has become critical in the immunotherapy era, and moving away from paradigms of the past has become mandatory 

There is a broader negligence of the public health consequences of individual actions among the health providers

There is a misunderstanding in what financial conflict of interests do on single people and what system implications they may have

Having treatment protocols for the rich countries and alternative protocols for the poor ones still nurtures global health disparities

People think cancer care is unaffordable because of the high prices of cancer medicines. Some state that innovations in oncology mostly happen thanks to massive investments in the private sector.

The scope of the oncology care across resource-diverse settings has been long debated.